Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: A meta-analysis of randomised controlled trials

International Journal of Clinical Practice

Volumn 65, Issue 5, 2011, Pages 602-612

  Giugliano, D ^a   Maiorino, M ^a   Bellastella, G ^a   Chiodini, P ^a   Esposito, K ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO;

ADULT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 79954552519     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02619.x     Document Type: Review

References (102)

1. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE,. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29: 2137-9. (Pubitemid 44871202)
2. DeFronzo RA, Stonehouse AH, Han J, Wintle ME,. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010; 27: 309-17.
3. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC,. The effect of oral antidiabetic agents on glycated hemoglobin levels: a systematic review and meta-analysis. Diabetes Care 2010; 33: 1859-64.
4. Food and Drug Administration. Draft guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. 2008. Available at Last accessed 16 September 2010.
5. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. 2002. Available at Last accessed 16 September 2010.
6. Skyler JS, Bergenstal R, Bonow RO, et al., Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119: 351-7.
7. Nathan DM, Buse JB, Davidson MB, et al., Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
8. Hirsch IB,. Insulin analogues. N Engl J Med 2005; 352: 174-83. (Pubitemid 40096614)
9. Hauber A, Gale EAM,. The market in diabetes. Diabetologia 2006; 49: 247-52. (Pubitemid 43185392)
10. Liberati A, Altman DG, Tetzlaff J, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W-65-94.
11. Giugliano D, Maiorino M, Bellastella G, Chiodini P, Esposito K,. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diab Res Clin Pract 2010. in press, doi:.
12. Stuart A, Ord JK,. Kendall's Advanced Theory of Statistics, 6th edn. London: Edward Arnold, 1994.
13. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
14. Riddle MC, Rosenstock J, Gerich J,. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-6. (Pubitemid 37339502)
15. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044. (Pubitemid 40353613)
16. Raskin P, Allen E, Hollander P, et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-5. (Pubitemid 40170923)
17. Heine RJ, Van Gaal LF, Johns D, et al., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-69.
18. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H,. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-9. (Pubitemid 40170922)
19. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B,. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005; 22: 374-81. (Pubitemid 40516233)
20. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, for the Atlantus Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-8. (Pubitemid 40756686)
21. Kann PH, Wascher T, Zackova V, et al., Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006; 114: 527-32. (Pubitemid 44870902)
22. Jacober SJ, Scism-Bacon JL, Zagar AJ,. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448-55. (Pubitemid 44349237)
23. Kazda C, Hülstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M,. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006; 20: 145-52. (Pubitemid 44316603)
24. Kennedy L, Herman WH, Strange P, Harris A, GOAL A1C Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006; 29: 1-8. (Pubitemid 44033422)
25. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P,. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-74. (Pubitemid 44125921)
26. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G,. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-9. (Pubitemid 44115353)
27. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E,. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-42. (Pubitemid 44366071)
28. Standl E, Maxeiner S, Raptis S, HOE901/4009 Study Group. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006; 38: 172-7.
29. Holman RR, Thorne KI, Farmer AJ, et al., 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-30. (Pubitemid 350005153)
30. Robbins DC, Beisswenger PJ, Ceriello A, et al., Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007; 29: 2349-64.
31. Barnett AH, Burger J, Johns D, et al., Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-48. (Pubitemid 350298125)
32. Esposito K, Ciotola M, Maiorino MI, et al., Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008; 149: 531-9.
33. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T,. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-84. (Pubitemid 351436611)
34. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G,. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-16.
35. Buse JB, Wolffenbuttel BH, Herman WH, et al., DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009; 32: 1007-13.
36. Raz I, Wilson PW, Strojek K, et al., Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32: 381-6.
37. Russell-Jones D, Vaag A, Schmitz O, et al., Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-55.
38. Blicklé JF, Hancu N, Piletic M, et al., Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009; 11: 379-86.
39. Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes Obes Metab 2009; 11: 623-31.
40. Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Hayes RP, Belin RM,. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. Diabetes Technol Ther 2009; 11 (Suppl 2): S63-73.
41. Strojek K, Bebakar WM, Khutsoane DT, et al., Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009; 25: 2887-94.
42. Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S,. A Randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naïve patients with type 2 diabetes. Diabetic Med 2010; 27: 181-8.
43. Heise T, Mathieu C, Hey-Hadavi J, Strack T, Lawrence D,. Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents. Diabetes Technol Ther 2010; 12: 135-41.
44. Kalra S, Plata-Que T, Kumar D, et al., Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Res Clin Pract 2010; 88: 282-8.
45. Swinnen SG, Dain MP, Aronson R, et al., A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010; 33: 1176-8.
46. Diamant M, Van Gaal L, Stranks S, et al., Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-43.
47. Strojek K, Shi C, Carey MA, Jacober SJ,. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 2010; 12: 916-22.
48. Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-6. (Pubitemid 30616801)
49. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB,. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-6. (Pubitemid 32888839)
50. Massi Benedetti M, Humburg E, Dressler A, et al., A one-years, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-96. (Pubitemid 36577862)
51. Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. a randomized, controlled trial. Ann Intern Med 2003; 138: 952-9.
52. Eliaschewitz FG, Calvo C, Valbuena H, et al., Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006; 37: 495-501. (Pubitemid 43675739)
53. Philis-Tsimikas A, Charpentier G, Clauson P, et al., Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28: 1569-81. (Pubitemid 44856694)
54. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al., Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-51. (Pubitemid 43277866)
55. Yki-Järvinen H, Juurinen L, Alvarsson M, et al., Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-9. (Pubitemid 46871139)
56. Pan CY, Sinnassamy P, Chung KD, et al., LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 2007; 76: 111-8. (Pubitemid 46240371)
57. Bunck MC, Diamant M, Cornér A, et al., One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial. Diabetes Care 2009; 32: 762-8.
58. Malone JK, Beattie SD, Campaigne BN, Johnson PA, Howard AS, Milicevic Z,. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract 2003; 62: 187-95. (Pubitemid 37414985)
59. Ushakova O, Sokolovskaya V, Morozova A, et al., Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. Clin Ther 2007; 29: 2374-84.
60. Nauck MA, Duran S, Kim D, et al., A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259-67.
61. Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M, Japan Diabetes Clinical Data Management Study Group. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008; 79: 171-6.
62. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S,. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20-5.
63. Yang W, Ji Q, Zhu D, et al., Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008; 31: 852-6.
64. Liebl A, Prager R, Binz K, et al., Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 45-52.
65. Raskin P, Matfin G, Schwartz SL, et al., Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes Obes Metab 2009; 11: 27-32.
66. Cucinotta D, Smirnova O, Christiansen JS, et al., Three different premixed combinations of biphasic insulin aspart-comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab 2009; 11: 700-8.
67. Oyer DS, Shepherd MD, Coulter FC, et al., INITIATEplus Study Group. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATE plus trial). Am J Med 2009; 122: 1043-9.
68. Rosenstock J, Lorber DL, Gnudi L, et al., Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010; 375: 2244-53.
69. Jain SM, Mao X, Escalante-Pulido M, Vorokhobina N, Lopez I, Ilag LL,. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010; 12: 967-75.
70. Roach P, Yue L, Arora V,. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999; 22: 1258-61. (Pubitemid 29350233)
71. Herz M, Sun B, Milicevic Z, et al., Comparative efficacy of preprandial or postprandial humalog@ Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther 2002; 24: 73-86. (Pubitemid 34117525)
72. Roach P, Arora V, Campaigne BN, Mattoo V, Rangwala S, The India Mix25/Mix50 Study Group. Humalog Mix50TM before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 2005; 5: 311-6.
73. Tigoviste CI, Strachinariu R, Farcasiu E, Milicevic Z, Teodirescu G,. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Rom J Intern Med 2003; 41: 152-62.
74. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I,. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 446-54. (Pubitemid 37483607)
75. Kilo C, Mezitisb N, Jainc R, Merseyd J, McGille J, Raskin P,. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003; 17: 307-13. (Pubitemid 37315939)
76. Schernthaner G, Kopp H-P, Ristic S, Muzyka B, Peter L, Mitteregger G,. Metabolic control in patients with type 2 diabetes using humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 2004; 36: 188-93. (Pubitemid 38510042)
77. Niskanen L, Jensen LE, RÃ¥stam J, Nygaard-Pedersen L, Erichsen K, Vora JP,. Randomized, multinational, open-label, 2-period,crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004; 26: 531-40. (Pubitemid 38586454)
78. Boehm BO, Vazb JA, Brbndstedb L, Home PD,. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Inter Med 2004; 15: 96-502.
79. Abrahamian H, Ludvik B, Schernthaner G, et al., Improvement of glucose tolerance in type 2 diabetic patients: traditional vs modern insulin regimens (results from the Austrian Biaspart Study). Horm Metab Res 2005; 37: 684-9. (Pubitemid 41810491)
80. Raz I, Stranks S, Filipczak R, et al., Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther 2005; 27: 1432-43. (Pubitemid 41598374)
81. Ligthelm R, Mouritzen U, Lynggaard H, et al., Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus regimen with four daily injections. A randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114: 511-9. (Pubitemid 44870900)
82. Kvapil M, Swatko A, Hilberg C, Shestakova M,. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab 2006; 8: 39-48.
83. Milicevic Z, Hancu N, Car N, Ivanyi T, Schwarzenhofer M, Jermendy G,. Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. Exp Clin Endocrinol Diabetes 2009; 117: 223-9.
84. Lund SS, Tarnow L, Frandsen M, et al., Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 2009; 339: b4324.
85. Bastyr EJ 3rd, Stuart CA, Brodows RG, et al., Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236-41.
86. Kawamori R, Iwamoto Y, Kadowaki T, et al., Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 900-9.
87. Gross JL, Nakano M, Colon-Vega G, et al., Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial. Diabetes Technol Ther 2009; 11 (Suppl 2): S27-34.
88. Anderson JH Jr, Brunelle RL, Keohane P, et al., Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1249-55. (Pubitemid 27251653)
89. Ross SA, Zinman B, Campos RV, et al., Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001; 24: 292-8. (Pubitemid 34100457)
90. Forst T, Eriksson JW, Strotmann HJ, et al., Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 97-103. (Pubitemid 36505818)
91. Bretzel RG, Arnolds S, Medding J, Linn T,. A direct efficacy and safety comparison of insulin aspart, uman soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004; 27: 1023-7. (Pubitemid 38579759)
92. Hollander P, Cooper J, Bregnhøj J, Pedersen CB,. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976-87.
93. Bergenstal RM, Johnson M, Powers MA, et al., Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 31: 1305-10.
94. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10: 1178-85.
95. Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L,. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009; 32: 1577-82.
96. Raskin P, Gylvin T, Weng W, Chaykin L,. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 542-8.
97. Fritsche A, Larbig M, Owens D, Häring H-U, on behalf of the GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes- Results of the GINGER study. Diabetes Obes Metab 2010; 12: 115-23.
98. Rašlová K, Bogoev M, Raz I, Leth G, Gall M-A, Hancu N,. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 193-201. (Pubitemid 39469347)
99. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W,. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
100. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M,. Effect of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract 2006; 73: 35-40. (Pubitemid 44226296)
101. Gale EAM, Beattie SD, Hu J, Koivisto V, Tan MH,. Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care 2007; 30: 2989-92. (Pubitemid 350255230)
102. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.